Ekso Bionics Holdings, Inc.

NasdaqCM:EKSO Stock Report

Market Cap: US$6.9m

Ekso Bionics Holdings (EKSO) Stock Overview

Designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. More details

EKSO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

EKSO Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

Ekso Bionics Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ekso Bionics Holdings
Historical stock prices
Current Share PriceUS$3.45
52 Week HighUS$22.95
52 Week LowUS$2.73
Beta0.81
1 Month Change-17.27%
3 Month Change-37.06%
1 Year Change-79.65%
3 Year Change-86.06%
5 Year Change-96.91%
Change since IPO-99.91%

Recent News & Updates

Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%

Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%

Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch

Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch

Recent updates

Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%

Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%

Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch

Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch
author-image

PRIA Healthcare And National Seating Will Streamline Medicare Claims

Strategic partnerships aim to broaden distribution, streamline reimbursements, and enhance revenue growth in the personal health market.

It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks

Mar 07
It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 06
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely

Jan 12
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely

Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper

Nov 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

Aug 29
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Jul 13
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20
Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Jun 19
Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics: Fragile Opportunity

Aug 24

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Jun 14
Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Shareholder Returns

EKSOUS Medical EquipmentUS Market
7D5.2%-0.4%-0.1%
1Y-79.6%9.3%13.0%

Return vs Industry: EKSO underperformed the US Medical Equipment industry which returned 9.9% over the past year.

Return vs Market: EKSO underperformed the US Market which returned 12.4% over the past year.

Price Volatility

Is EKSO's price volatile compared to industry and market?
EKSO volatility
EKSO Average Weekly Movement13.7%
Medical Equipment Industry Average Movement7.9%
Market Average Movement6.4%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: EKSO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EKSO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200564Scott Daviswww.eksobionics.com

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs.

Ekso Bionics Holdings, Inc. Fundamentals Summary

How do Ekso Bionics Holdings's earnings and revenue compare to its market cap?
EKSO fundamental statistics
Market capUS$6.93m
Earnings (TTM)-US$10.79m
Revenue (TTM)US$17.54m
0.4x
P/S Ratio
-0.6x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EKSO income statement (TTM)
RevenueUS$17.54m
Cost of RevenueUS$8.18m
Gross ProfitUS$9.37m
Other ExpensesUS$20.16m
Earnings-US$10.79m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.57
Gross Margin53.39%
Net Profit Margin-61.51%
Debt/Equity Ratio38.2%

How did EKSO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/10 06:06
End of Day Share Price 2025/07/10 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ekso Bionics Holdings, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory ChodaczekB. Riley Securities, Inc.
Craig BijouCantor Fitzgerald & Co.
Gregory ChodaczekCRT Capital Group